We evaluated MYCN/ALK gene copy number by fluorescence in situ hybridization (FISH) and detected ALK protein expression by immunohistochemistry (IHC) in 188 NBL, 52 GNBL and 6 GN samples and analyzed their association with clinical outcome of the patients.     ///    A better prognosis trend was observed in patients with MYCN/ALK gain tumors compared with those with MYCN/ALK normal tumors.     ///    ALK positivity in NTs correlated with advanced tumor types and MYCN/ALK gene copy number increases.     ///    "In addition, ALK positivity also significantly correlates with MYCN/ALK gene copy number increases (P<0.05). "    ///    Kaplan-Meier survival analysis indicated that MYCN/ALK amplification is correlated with decreased overall survival in NBL. 